Kenji Yasukawa, Astellas CEO (Akio Kon/Bloomberg via Getty Images)
January 20, 2023 11:09 AM ESTUpdated 01:53 PM
Cell/Gene Tx
FDA+

FDA lifts clin­i­cal hold on Astel­las’ Pompe gene ther­a­py

Lei Lei Wu

News Reporter

The FDA has lift­ed a clin­i­cal hold on Astel­las Phar­ma’s Pompe dis­ease gene ther­a­py tri­al, the Japan­ese com­pa­ny an­nounced Fri­day morn­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times